Skip to content
akaturk Academic measurement

Article detail · 2021

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma

Journal

New England Journal of Medicine

ISSN 0028-4793

YÖKSİS OpenAlex Open access · bronze SJR Q1 JCR Q1 Citations 282 Top 1% Percentile 99.7% FWCI 20.19
Year
2021
Type
article

Data source split

  • YÖKSİS YÖKSİS article record
  • YÖKSİS venue New England Journal of Medicine
  • Catalog match (ISSN) New England Journal of Medicine
  • OpenAlex OpenAlex enrichment (abstract, citations, topics)

Abstract

OpenAlex · English

BACKGROUND: Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well as with other type 2 inflammatory diseases. METHODS: ) at week 12 and in the score on the Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) at week 24. End points were evaluated in the two primary efficacy populations who had either a type 2 inflammatory asthma phenotype (≥150 blood eosinophils per cubic millimeter or a fraction of exhaled nitric oxide of ≥20 ppb at baseline) or a blood eosinophil count of at least 300 cells per cubic millimeter at baseline. RESULTS: was 10.5±1.0 percentage points with dupilumab and 5.3±1.4 percentage points with placebo (mean difference, 5.2 percentage points; 95% CI, 2.1 to 8.3; P<0.001). Dupilumab also resulted in significantly better asthma control than placebo (P<0.001). Similar results were observed in the patients with an eosinophil count of at least 300 cells per cubic millimeter at baseline. The incidence of serious adverse events was similar in the two groups. CONCLUSIONS: Among children with uncontrolled moderate-to-severe asthma, those who received add-on dupilumab had fewer asthma exacerbations and better lung function and asthma control than those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; Liberty Asthma VOYAGE ClinicalTrials.gov number, NCT02948959.).

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

282 citations

OpenAlex cited_by_count (cache / database)

2 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria 2026 Citations 45 · OpenAlex
  2. Mechanisms and therapeutic potential of epithelial-immune crosstalk in airway inflammation 2025 Citations 4 · OpenAlex

Authors

  1. Leonard B BAcharier
  2. Jorge F Maspero
  3. Constance H Katelaris
  4. Alessandro G Fiocchi
  5. Remi Gagnon
  6. İnes de Mir
  7. Neal Jain
  8. Lawrence D Sher
  9. Xuezhou Mao
  10. Dongfang Liu
  11. Yi Zhang
  12. Asif H Khan
  13. Upender Kapoor
  14. Faisal A Khokhar
  15. Paul J Rowe
  16. Yamo Deniz
  17. Marcella Ruddy
  18. Elizabeth Laws
  19. Naimish Patel
  20. David M Weinreich
  21. George D Yancopoulos
  22. Nikhil Amin
  23. Leda P Mannent
  24. David J Lederer
  25. Megan Hardin
  26. Liberty Asthma VOYAGE Investigators
  27. FİGEN GÜLEN EGE ÜNİVERSİTESİ